Sanofi aims for Nexviazyme approval in younger Pompe disease patients

Data ReadoutpositiveNexviazymePositive

AI Analysis

Summary

Sanofi's Nexviazyme met all primary and secondary endpoints in the Baby-COMET trial for younger Pompe disease patients, supporting potential label expansion in this indication.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Met all primary and secondary endpoints in Baby-COMET trial

Importance:7/10

Sentiment:

0.70

Pompe diseaselabel expansionrare diseaseBaby-COMETpediatric

Related Companies

$SNY

Read the original article

Published by Clinical Trials Arena on July 1, 2026 1:57 PM

Read Original